Clinical Trial Search

Primary: Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders — 17; 11; 10 participants

Primary: Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year — 7; 5; 5 Participants

Primary: Objective Response (OR) — 0 Participants with OR

Primary: Percentage of Participants With Response — 23.3 percentage of participants

Primary: Epicardial Coronary Artery Endothelial Function (Adjusted) at Week 16 Comparing the Eplerenone Group to the Placebo Group — -1.2; -10.7 % change wk16-%change wk0…

Primary: Pharmacokinetics of Tigecycline Along With Standard Treatments for Clostridium Difficile — 0.18 milligrams/liter

Primary: Adjusted Mean Change in Total Body Weight — -0.88; -2.96 kg — p=<0.0001

Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -11.8; -10.4 units on a scale — p=0.176

Primary: Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14 — 24.9; 58.5 Percentage of Participants — p=<0.001

Primary: Integration Success of Implant — 17; 20 participants

Primary: Proportion of Patients With Histologically Confirmed Recurrence Within One 1 Year. — 30.5; 47.3 precentage of participants — p=0.05

Primary: Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White Light — 16.4 percentage of participants

Primary: Implants Not Mobile (Not Failing) at End of 3 Years — 158; 140 dental implant

Primary: Change in the 17 Item Hamilton Rating Scale for Depression (HAM-D-17) Score — -9.91; -7.41 units on a scale

Primary: Serum Bactericidal Activity Against MenC — 6786; 6278; 2061; 1746 GMTs